Status:
RECRUITING
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Lead Sponsor:
Ain Shams University
Conditions:
Chronic Kidney Disease Stage 5
CKD Stage 4
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidne...
Detailed Description
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally developed as oral antihyperglycemic agents for managing type 2 diabetes, have quickly gained recognition for their broad therapeutic benef...
Eligibility Criteria
Inclusion
- Adult patients aged eighteen or older.
- Patients with advanced chronic kidney disease (i.e., eGFR \< 20 mL/min/1.73m2)not on dialysis
Exclusion
- Autosomal dominant polycystic kidney disease (ADPKD).
- Type 1 diabetes mellitus
- Patients on SGLT2 inhibitors.
- History of ketoacidosis in the last 3 months.
- Known hypersensitivity to SGLT2 inhibitors.
- Known hepatic impairment.
- Pregnant or breastfeeding females.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06982079
Start Date
May 1 2025
End Date
November 1 2026
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Egypt